Skip to main content
. 2012 Sep 25;47(3):194–201. doi: 10.5045/kjh.2012.47.3.194

Fig. 2.

Fig. 2

Flow cytometry analysis results show that deferasirox treatment increased the percentage of cells in sub-G1 phase in a dose-dependent manner. (A) NCI H28:N78 cells, (B) Jiyoye cells, and (C) Ramos cells. The results are presented as mean (SD) percentage of cells in sub-G1 from triplicate experiments (a)P<0.05, b)P<0.01).